6th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference
22
Jun
-
23
Jun
2023
When
Boston
USA
Where

Our 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 22nd - 23rd June 2023, in Boston, would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.
This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy.

Similar Events

You May Like

Event

MarketsandMarkets

0/5
(0)

In the decade of the 2020s, the B2B world will see $25 trillion worth of disruptive revenue shifts. Organizations globally are navigating both the opportunities and risks that are consequent.

22 - 23 Jun 2023
In-Person

Speakers and Delegates
Industry Experts and Thought Leaders

Scientist
President & Chief Scientific Officer
Executive Vice President and Chief Medical Officer
Principal Scientist
Senior Scientist
Co-founder & Chief Scientific Officer
Executive Medical Director, Clinical Development

Sponsors and Exhibitors
Brand, Media and Promotional Partners

LARVOL

Customized intelligence reports and SaaS solutions - We provide healthcare and life sciences experts accurate, rapid, expertly-curated information to enable strategic decision-making.

Biocytogen

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities.

Veracyte, Inc.

Veracyte is a pioneering genomic diagnostics company. Our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods.

Proteome Sciences plc

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.

Sanyou Biopharmaceuticals Co., Ltd.

Sanyou Biopharmaceuticals Co., Ltd. is a leading international biological high-tech enterprise focusing on R&D and services of innovative antibody drugs.

EpigenDx, Inc.

EpigenDx was incorporated in 2006 as a genomic and epigenomic research company specializing in disease biomarker discovery, validation and molecular diagnosis, with an unmatched expertise in the field of DNA methylation analysis.

Organizer

Get emails from us

Thank you
Oops! Something went wrong